Flaws In China’s Drug Regulatory Process Revealed In Herbal Injection Recall
This article was originally published in PharmAsia News
China's Ministry of Health and State FDA have issued an urgent notice to recall two batches of Ciwujia injection produced by Wandashan Pharmaceutical after adverse effects resulting in three deaths were reported. Although the investigation is still ongoing, experts think that the deaths were mainly caused by impurities in the herbal injection. For food and drug supervision, China currently only tests active components. Control is lax on impurities testing; furthermore, the complex nature of traditional Chinese medicine components means some impurities cannot be detected. Industry analysts observe that despite the country's repeated adverse drug incidents, the negative impact on TCM injections will probably be short term as the products still have big market potential due to their low cost. (Click here for more - Chinese Language)
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.
From the rise of DTC to the shadow of Caronia, Abrams, the long-time head of the Office of Prescription Drug Promotion, monitored dramatic changes in the pharmaceutical marketplace and regulatory environment. He retired from FDA on 23 October after a tenure marked as much by careful research projects and copious guidances as it was by promotional and legal upheavals.